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Introduction
Non-Hodgkin’s lymphomas (NHL) represent 90% of all lymphomas 
[1] and most commonly occur in lymph nodes or lymphoid tissue 
of the thymus, spleen, bone marrow or Waldeyer’s ring (tonsils, base 
of the tongue and nasopharynx). Extra-nodal NHL accounts for 
approximately one fifth of all cases, and the most frequent locations are 
the lung, gastrointestinal tract, nervous system and skin [1]. Lymphomas 
involving the female genital tract are rare, and those originating from 
this region are extremely uncommon. Primary NHL of the female genital 
tract account for less than 0.5% of all gynaecological malignancies [2]. 
As primary sites of NHL, the uterus and cervix are very uncommon 
and account for 0.5% of extra-nodal lymphomas [3,4]. The majority 
of NHLs arising from the uterus and cervix are aggressive lymphomas 
of diffuse large B-cell NHL type (DLBCL) [5]. The presentation of 
uterine lymphoma is often subclinical; hence diagnosis can be difficult, 
especially in the differential diagnosis of common neoplasms such as 
fibroids or sarcomas [6]. Symptoms of patients with cervical lymphomas 
may include vaginal bleeding, perineal discomfort and/or vaginal 
discharge. As cervical lymphomas often arise from the cervical stroma 
the epithelium is initially preserved and therefore PAP smears during 
routine cervical screening are often normal.
Due to the rarity of uterine and cervical lymphomas treatment is 
usually highly individualized. Surgery usually plays a limited role as 
therapeutic modality as gynaecological lymphomas are commonly 
radio- and chemotherapy-sensitive [7], and is predominantly used for 
initial diagnosis.
We report on four cases of primary large B-cell lymphomas (LBCL) 
of the uterus and cervix. Other potential origins of disease were excluded 
clinically and radiologically. Two patients were successfully treated with 
chemotherapy, one with the addition of involved field radiotherapy post 
chemotherapy, while two had surgery followed by chemotherapy.
Abstract
Objective: Primary malignant non-Hodgkin’s lymphomas in the female genital tract are rare, accounting for less 
than 1% of all extranodal non-Hodgkin’s lymphomas.
Methods/materials: We report on four cases of primary non-Hodgkin’s lymphomas of the uterus and cervix. Three 
of our patients were confirmed to be diffuse large B-cell lymphomas (LBCL) and one patient to be T-cell rich LBCL on 
histopathological examination and immunohistochemical study. One of our three patients who presented with diffuse 
LBCL was diagnosed with intravascular diffuse LBCL. Other potential origins of disease were excluded.
Results: Two patients were successfully treated with chemotherapy, one with the addition of involved field 
radiotherapy post chemotherapy, while two had surgery followed by chemotherapy. All four patients are in complete 
remission with follow up period ranging from 6 months to 5 years.
Conclusions: Gynaecological lymphomas can be a diagnostic challenge due to unspecific symptoms. However, 
when diagnosed and treated they have a good prognosis. Clinicians should therefore include lymphoma in their 
differential diagnosis when investigating gynaecological symptoms.
Results
Case 1
34-year-old, gravida 0, presented with intermenstrual bleeding 
during evaluation of infertility. She did not have any B-symptoms 
(night sweats, weight loss and fever) and had previously been healthy. 
However, there was a medical history of chronic idiopathic neutropenia, 
not requiring treatment, and mild asthma. A pelvic ultrasound 
demonstrated a normal appearing uterus and ovaries and no cause for 
her symptoms was identified. On gynaecological examination a cervical 
mass was noted and a PAP smear was taken which showed a low grade 
squamous intraepithelial lesion and abnormal cells consistent with 
human papillomavirus (HPV) infection. However, a cervical biopsy 
showed NHL of large cell type, positive for CD20 and BCL6 with a 
GCB phenotype. CT imaging revealed a 55 × 71 mm cervical mass with 
enlarged bilateral pelvic lymph nodes (17 × 13, 20 × 16, 15 × 12 mm) 
and a prominent left axillary lymph node (7 × 5 mm). Subsequent PET 
imaging showed an intensely FDG avid large cervical mass, bilateral 
external iliac and left axillary lymph nodes and low grade FDG activity 
throughout the bone marrow, with a normal liver and spleen. FISH 
testing was negative for cMYC. Final diagnosis was DLBCL. The patient 
received primary chemotherapy consisting of 6 cycles of R CHOEP 14 
(C, Cyclophosphamide H, Doxorubicin Hydrochloride O, Vincristine 
(Oncovin) E, Etoposide P, Prednisolone) and had Goserelin (ZoladexTM) 
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injections for ovarian protection. CT imaging at the end of treatment 
after 4 months showed a normal cervix and no lymphadenopathy. The 
PET scan was also normal. 
A cervical biopsy which was taken due to an inconclusive Pap 
smear after the treatment did not show any residual lymphoma. After 
six months, the patient remains in complete remission.
Case 2
57-year-old patient presented with a 12 months history of 
intermittent irregular postmenopausal bleeding. She did not have any 
B-symptoms and had previously been healthy. An MRI scan revealed 
a 5 cm cervical mass with a left obturator lymph node measuring 16 
× 20 mm and two iliac chain nodes measuring 19 × 14 mm and 28 
× 15 mm, respectively. Subsequent CT and PET imaging showed no 
other lymphadenopathy or disease outside of the pelvis. Fine needle 
aspiration of the cervix revealed lymphoma. CT guided biopsy of the 
left iliac chain node was suspicious of intermediate grade lymphoma 
as CD 10, CD 19 and CD 20 were positive. Final diagnosis was DLBCL 
in a background of follicular lymphoma. Bone marrow biopsy was 
normal but PET imaging showed findings consistent with FDG avid 
lymphomatous disease in the distal aspect of the uterus/cervix and 
lymph node metastasis involving the left iliac lymph nodes. The 
patient was treated with 6 cycles of R CHOP 21 and involved field 
radiotherapy. Restaging imaging after 5 months of treatment showed 
no pathologically enlarged pelvic or abdominal lymph nodes on CT 
scan and normalization of the PET. The patient remains in complete 
remission after 5 years.
Case 3
58-year-old patient presented with three episodes of postmenopausal 
spotting over 4 months but without any B symptoms. She did not have 
any significant surgical or medical history. Curettage of the uterus 
was performed and showed a malignancy suspicious for a sarcoma in 
the histopathology. CT imaging showed an unremarkable uterus but 
para-aortic lymphadenopathy. The patient underwent an abdominal 
hysterectomy, bilateral salpingo-oophorectomy and para-aortic lymph 
dissection. Intraoperatively the uterus was found to be mobile and 
not enlarged but there was a 10 cm to 12 cm mass in the small bowel 
mesentery extending up to the pancreas. On opening, the uterus had 
a polypoid lesion within the cavity which in the histopathology was 
found to be a T cell rich B cell NHL. Postoperative PET imaging showed 
increased FDG uptake within left supraclavicular, paraoesophageal, 
porta hepatis and mesenteric lymph nodes. It also showed skeletal 
uptake in the T9 and T12 vertebral bodies, right iliac bone adjacent 
to the sacro-iliac joint and the left femoral neck. Final diagnosis was 
a T-cell rich BCL. The patient was treated with 6 cycles of R-CHOP 
21 chemotherapy. Post chemotherapy PET imaging showed no FDG 
avid residual disease. The patient had 3 years of follow up and was in 
complete remission. Her blood count occasionally demonstrated mild 
leukopenia and thrombocytopenia but remained stable otherwise.
Case 4
61-year-old patient presented with an S1 distribution of right 
leg discomfort and paraesthesia following a two month history of 
atypical migraine, as well as a left paracentral visual disturbance with 
increased colour perception. Initially the patient did not have any B 
symptoms but later developed both weight loss and night sweats. She 
had previously been healthy. An MRI of the lumbar spine and sciatic 
nerve was normal. Nerve conduction studies were most suggestive of 
L5/S1 radiculopathy. On review two weeks later, the right leg weakness 
had progressed and was now global with an absent ankle reflex. The 
patient developed reduced perineal sensation as well as difficulties 
passing urine. Ascending sensory deficits were observed, as well as 
a new onset of pyramidal pattern weakness in the left leg, with brisk 
knee jerk and an extensor plantar response. By this time, she had also 
developed constitutional symptoms of lethargy, night sweats and 5 kg 
weight loss within one month. A PET scan demonstrated abnormal 
uptake in the lung apices and bilateral hilar regions, diffuse myometrial 
activity and diffuse uptake in the bone marrow. Repeat MRI of the brain 
and full spine demonstrated abnormal meningeal infiltrative disease 
as well as diffuse enhancement of the pachymeninges. There was 
also a widespread marrow abnormality consistent with an infiltrative 
process. The patient underwent a bone marrow biopsy which revealed a 
hyperplastic marrow with evidence of haemophagocytosis and a single 
lymphoid aggregate. Given the FDG avidity of the myometrium on 
PET, a hysteroscopy and laparoscopy were performed. Hysteroscopy 
revealed a slightly thickened endometrium with a small uterine polyp. 
On laparoscopy, opaque ascites and a bulky uterus were identified. 
Histology from uterine curettage showed a large cell malignancy 
consistent with a large cell lymphoma. The patient had a robotic 
hysterectomy, bilateral salpingo-oophorectomy and pelvic lymph 
node sampling. Histology of the uterine wall and pelvic lymph nodes 
revealed an intravascular large B-cell lymphoma. The patient was 
treated with R-CVP with intrathecal methotrexate as initial debulking 
therapy followed by six cycles of R-Hyper CVAD chemotherapy. A 
post chemotherapy PET scan revealed no FDG avidity. The patient has 
remained in full remission for 4 years.
Discussion
NHL in general and extra-nodal NHL in particular has increased 
in incidence over the last decades; the reason for this is unclear [8]. It 
has been suggested that the aetiology of NHL may include infectious 
diseases, such as HIV, immunosuppressive drugs and exposure to 
environmental agents, such as pesticides and pollutants [9]. Primary 
lymphomas of the uterus and cervix are very rare, with less than 
1% of patients with any type of lymphoma presenting with this site 
of disease. In a study by Kosari, et al. which analysed 117 cases of 
lymphomas involving the genital tract in female patients, 63% were 
classified as primary lymphomas of the female genital tract and 37% 
as secondary involvement [10]. Most commonly affected sites were the 
adnexa (56%), followed by uterine corpus (15%) and cervix (11%) [10]. 
The World Health Organization classifies lymphoid neoplasms into 
subgroups of mature B-cell neoplasms, mature T and NK neoplasms, 
Hodgkin lymphomas, post-transplant lymphoproliferative disorders 
and histiocytic and dendritic cell neoplasms [11]. Regardless of the 
site of involvement, DLBCL is the most common histological subtype 
in the female genital tract. The mean age in our case series was 52.5 
years (range 34-61 years) which is consistent with the mean age of 50.4 
years in previous reports [10]. Three of our patients were diagnosed 
with DLBCL and one patient had T-cell rich LBCL. One of our three 
patients who presented with DLBCL was diagnosed with intravascular 
DLBCL. Intravascular large B-cell lymphoma is a very rare subtype of 
DLBCL with an estimated incidence of less than one in a million in the 
population. The first case of primary intravascular large B cell lymphoma 
of the uterus was reported in 2004 [12]. Intravascular lymphomas (IVL) 
usually present in the central nervous system or skin [13]. IVL of the 
uterus or cervix are extremely rare and to our knowledge only seven 
cases has been reported in the literature [12,14-19]. Because of the rarity 
of IVL and the variability of the clinical presentation, the diagnosis is 
often made at autopsy [13]. Diagnosis of IVL is almost exclusively made 
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by biopsy of a involved site [13]. In our case a uterine curettage proved 
to be insufficient to obtain the correct diagnosis. The final diagnosis of 
IVL was made on the hysterectomy specimen. 
Since gynecological lymphomas are often either subclinical or 
mimic other genital tumors or disorders, they can be difficult to 
diagnose and differentiate from more common conditions. Presenting 
symptoms can be abdominal pain, vaginal bleeding and discharge, 
dyspareunia and/or symptoms of a pelvic mass [20]. Pap smears of the 
cervix are usually negative, likely due to the fact that most lymphomas 
are frequently located in the sub-epithelial layer of the cervix [21]. In 
our case series three patients presented with bleeding disorders (two 
with postmenopausal and one with intermenstrual bleeding) and one 
patient with right leg discomfort and paranesthesia after two months 
of atypical migraine with visual disturbance. Systemic complaints are 
common in lymphoma patients, and up to 40 percent of patients with 
NHL present with fever, weight loss, or night sweats (i.e. B symptoms) 
[22]. The clinical examination is often focused on detection of potentially 
involved lymphoid sites; palpable adenopathy or hepatosplenomegaly 
and the findings of these symptoms are important in determining 
prognosis [23]. In this study, only one of our patients (case 4) developed 
B symptoms, however, with some delay.
To enable prompt diagnosis and treatment of uterine and cervical 
lymphomas, clinicians should keep in mind that the presentation may 
be non-specific, and a high index of suspicion is therefore required. 
On imaging the appearance of uterine and cervical lymphomas can 
vary but diffuse enlargement of the uterus without disruption of the 
endometrial epithelium has been reported to be a characteristic finding 
[24]. Most commonly the uterine tumour is heterogeneous due to sites 
of haemorrhage, calcifications and necrosis [24]. Three of our patients 
had a normal appearing uterus on imaging at presentation. Only one 
case (case 4) had thickened endometrium with a polyp and an enlarged 
bulky uterus. The apparent normal appearance of the uterus can be 
misleading, and potentially delay diagnosis. 
Definitive diagnosis of lymphoma always requires a biopsy and 
histopathological assessment with immunohistochemistry and 
fresh tissue for flow cytometry. In our cases the histopathological 
examination revealed LBCL in all cases (Figures 1 and 2). The results of 
the immunohistochemistry are summarized in Table 1.
The Ann Arbour staging system, developed in 1971, was initially 
used solely for staging Hodgkin lymphomas, however, has subsequently 
been adapted to include also NHL. The staging criteria for the four 
stages are the number and location of affected lymph node regions and/
or extra-nodal sites. The presence or absence of B symptoms is also 
incorporated into the staging system. It has been suggested that staging 
plays a lesser role in determining prognosis compared to histological 
features and is more useful in deciding when patients may benefit 
from more than one treatment modality [25]. The disease stages of our 
patients are shown in Table 1. 
The rarity of patients presenting with primary gynaecological 
lymphoma contributes to the difficulties of diagnosis and lack of 
consensus regarding treatment. Lymphomas are usually very chemo- 
and radiosensitive and consequently surgery has only a limited role [7]. 
However, it is not uncommon for the final diagnosis to be made after 
surgery (as in patient 3 and 4). In those cases, histopathology of the 
curettings was suspicious for sarcoma (case 3) and large cell lymphoma 
(case 4) whilst subsequent definitive surgery showed a T-cell rich B-cell 
NHL in one case (case 3) and intravascular LBCL in the other (case 4). 
In some lymphomas of the female genital tract a hysterectomy could 
be regarded as an important diagnostic procedure to make the correct 
diagnosis. However, none of the hysterectomies was performed for 
therapeutic purposes.
Traditionally, the recommended treatment for DLBCL has been 
chemotherapy ± radiotherapy [20]. Lately, other modalities such 
allogeneic bone-marrow transplantation, monoclonal antibodies and 
high-dose chemotherapy have shown improved outcomes [7]. In our 
case series, all patients were treated with chemotherapy ± monoclonal 
anti CD Ab Rituximab. One patient received additional radiotherapy. 
The reported 5-year survival of primary cervical and uterine 
lymphomas in the literature is approximately 80% [26]. However, the 
prognosis for IVL is generally poor [27,28]. In a review from Yamamoto 
et al. on five cases with uterine IVL, two died within 5 months, two after 
10 months and one 51 months after diagnosis [17]. In our case series, all 
patients remain in full remission after follow up ranging from 6 months 
to 5 years. The prognosis of aggressive NHL can be calculated using the 
revised international prognostic index (R-IPI) which includes age, Ann 
Arbor stage, hemoglobin level, serum LDH level, and number of nodal 
sites [29]. The prognostic index identifies three distinct prognostic 
groups (very good, good and poor). Patients with no risk factors (very 
good prognosis) show more than 90% long-term progression free 
survival, patients with 1 or 2 risk factors (good prognosis) 80% and 
patients with 3-5 risk factors (poor prognosis) have a long-term chance 
of cure in 50%. 
Our cases showed IPI ranging from 0-3 (Table 1).
Figure 1: Diffuse large B-cell lymphoma of uterine cervix (Case 3).
Figure 2: Immunohistochemistry showing CD20 positivity (Case 3).
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Conclusion
Although the incidence of NHL is increasing, primary gynaecological 
lymphomas are rare and can be a diagnostic challenge due to unspecific 
symptoms resembling other more common conditions. However, when 
diagnosed and treated with aggressive chemotherapy, gynaecological 
lymphomas commonly have a good prognosis. Clinicians should 
therefore Include lymphoma in their differential diagnosis when 
investigating gynaecological symptoms.
References
1. Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. 
Lancet 380: 848-857.
2. Yamada T, Iwao N, Kasamatsu H, Mori H (2003) A case of malignant lymphoma 
of the ovary manifesting like an advanced ovarian cancer. Gynecol Oncol 90: 
215-219.
3. Chorlton I, Karnei RF, King FM, Norris HJ (1974) Primary malignant 
reticuloendothelial disease involving the vagina, cervix, and corpus uteri. 
Obstet Gynecol 44: 735-748.
4. Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, et al. (2006) Primary 
lymphomas of the cervix and uterus: The University of Pennsylvania’s 
experience and a review of the literature. Leuk Lymphoma 47: 1894-901.
5. Garavaglia E, Taccagni G, Montoli S, Panacci N, Ponzoni M, et al. (2005) 
Primary stage I-IIE non-Hodgkin’s lymphoma of uterine cervix and upper 
vagina: Evidence for a conservative approach in a study on three patients. 
Gynecol Oncol 97: 214-218.
6. Vang R, Medeiros LJ, Ha CS, Deavers M (2000) Non-Hodgkin’s lymphomas 
involving the uterus: A clinicopathologic analysis of 26 cases. Mod Pathol 13: 
19-28.
7. Berthold D, Ghielmini M (2004) Treatment of malignant lymphoma. Swiss 
medical weekly. 134: 472-480.
8. Hanprasertpong J, Hanprasertpong T, Thammavichit T, Kongkabpan D, 
Tungsinmunkong K, et al. (2008) Primary non-Hodgkin,s lymphoma of the 
uterine cervix. Asian Pac J Cancer Prev 9: 363-366.
9. Trenhaile TR, Killackey MA (2001) Primary pelvic non-Hodgkin’s lymphoma. 
Obstet Gynecol 97: 717-720.
10. Kosari F, Daneshbod Y, Parwaresch R, Krams M, Wacker HH (2005) 
Lymphomas of the female genital tract: A study of 186 cases and review of the 
literature. Am J Surg Pathol 29: 1512-1520.
11. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, et al. (2016) The 2016 
revision of the World Health Organization classification of lymphoid neoplasms. 
Blood 127: 2375-2390.
12. Sur M, Ross C, Moens F, Daya D (2005) Intravascular large B-cell lymphoma of 
the uterus: A diagnostic challenge Int J Gynecol Pathol 24: 201-203.
13. Zuckerman D, Seliem R, Hochberg E (2006) Intravascular lymphoma: The 
oncologist’s “great imitator”. The oncologist 11: 496-502.
14. Yamada N, Uchida R, Fuchida S, Okano A, Okamoto M, et al. (2005) CD5+ 
Epstein-Barr virus-positive intravascular large B-cell lymphoma in the uterus 
co-existing with huge myoma. Am j hematol 78: 221-224.
15. Lannoo L, Smets S, Steenkiste E, Delforge M, Moerman P, et al. (2007) 
Intravascular large B-cell lymphoma of the uterus presenting as fever of 
unknown origin (FUO) and revealed by FDG-PET. Acta Clin Belg 62: 187-190.
16. Davey DD, Munn R, Smith LW, Cibull ML (1990) Angiotrophic lymphoma. 
Presentation in uterine vessels with cytogenetic studies. Arch Pathol Lab Med 
114: 879-882.
17. Yamamoto T, Morita K, Iriyama N, Wakui K, Hiroi A, et al. (2011) Intravascular 
large B-cell lymphoma of the uterus: A case with favorable clinical outcome. Int 
J Surg Pathol 19: 672-676.
18. Xia Y, Wang Y, Jiang Y, Yu W, Li Y, et al. (2014) Primary intravascular large B 
cell lymphoma of the endometrium. Acta Histochem 116: 993-996.
19. Shigematsu Y, Matsuura M, Nishimura N, Tsuyama N, Takeuchi K, et al. (2016) 
Intravascular Large B-cell Lymphoma of the Bilateral Ovaries and Uterus in an 
Asymptomatic Patient with a t(11;22) (q23;q11) Constitutional Translocation. 
Internal Med 55: 3169-3174.
20. Signorelli M, Maneo A, Cammarota S, Isimbaldi G, Garcia Parra R, et al. 
(2007) Conservative management in primary genital lymphomas: The role of 
chemotherapy. Gynecol Oncol 104: 416-421.
21. King JA, Elkhalifa MY, Michael C (1997) Malignant lymphoma identified on a 
cervical cytologic smear, with immunophenotypic analysis. Acta Cytol 41: 1228-
1230.
22. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, et al. (1982) 
Malignant lymphoma. 1. The histology and staging of 473 patients at the 
National Cancer Institute. Cancer 50: 2699-26707.
23. Weingertner AS, Hamid D, Roedlich MN, Baldauf JJ (2004) Non-Hodgkin 
malignant lymphoma revealed by an ovarian tumor case report and review of 
the literature. Gynecol Oncol 95: 750-754.
24. Park SB, Lee YH, Song MJ, Cho HC, Lee MS, et al. (2012) Sonographic 
findings of uterine cervical lymphoma manifesting as multinodular lesions. Clin 
Imaging 36: 636-638.
25. Ansell SM (2015) Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin 
Proc 90: 1574-1583.
26. Onyiuke I, Kirby AB, McCarthy S (2013) Primary gynecologic lymphoma: 
Imaging findings. AJR 201: 648-655.
Case 1 Case 2 Case 3 Case 4
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